🔎 Trials Near Me

Home › Major Depressive Disorder › NCT07196501

A Study to Evaluate the Maintenance Effect of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

RecruitingPhase 3

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Maintenance of Effect of NBI-1065845 as an Adjunctive Treatment in Subjects With Major Depressive Disorder (MDD)

Who can join

Ages 18 and older · All sexes

Full eligibility criteria
Key Inclusion Criteria:

* Participant has a primary diagnosis of recurrent MDD (moderate or severe) or persistent depressive disorder.
* Participant has had an inadequate response to oral antidepressant treatments in the current episode of depression.
* Participant must have been taking oral antidepressants for at least 8 weeks and is willing to continue the same oral antidepressants at the same dose and frequency of administration throughout participation in the study.
* Total Hamilton Depression Rating Scale-17 Item (HAM-D17) score ≥22 at screening and at study baseline (Day 1).
* Willing and able to comply with all study procedures and restrictions in the opinion of the investigator.

Key Exclusion Criteria:

* A current or prior psychiatric disorder diagnosis in the last 1 year that was the primary focus of treatment other than MDD.
* Are considered by the investigator to be at imminent risk of suicide or injury to self or others.
* Participants depressive symptoms have previously demonstrated nonresponse to electroconvulsive therapy (ECT) in the current major depressive episode.

Note: Other protocol-defined Inclusion and Exclusion criteria may apply.

About the study

The primary objective of this study is to evaluate the efficacy of NBI-1065845 compared with placebo as an adjunctive treatment in delaying relapse of depressive symptoms (maintenance of effect) in participants with MDD.

What is being tested

Sponsor: Neurocrine Biosciences · Participants: 550 · Started: Aug 18, 2025

Contact the study team

Official record on ClinicalTrials.gov — NCT07196501

Locations in the U.S.

CaliforniaNeurocrine Clinical Site, Oceanside
Neurocrine Clinical Site, Orange
Neurocrine Clinical Site, San Jose
ConnecticutNeurocrine Clinical Site, New Haven
FloridaNeurocrine Clinical Site, Miami Gardens
Neurocrine Clinical Site, Orlando
Neurocrine Clinical Site, Palm Bay
Neurocrine Clinical Site, Tampa
IowaNeurocrine Clinical Site, Iowa City
LouisianaNeurocrine Clinical Site, Marrero
MissouriNeurocrine Clinical Site, O'Fallon
New MexicoNeurocrine Clinical Site, Albuquerque
New YorkNeurocrine Clinical Site, Glen Oaks
North CarolinaNeurocrine Clinical Site, Charlotte
OklahomaNeurocrine Clinical Site, Edmond
Neurocrine Clinical Site, Oklahoma City
PennsylvaniaNeurocrine Clinical Site, Philadelphia
TexasNeurocrine Clinical Site, Bellaire
Neurocrine Clinical Site, Stafford
Neurocrine Clinical Site, Wichita Falls
UtahNeurocrine Clinical Site, Draper
VirginiaNeurocrine Clinical Site, Roanoke

Conditions

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.